Treatment of the antiphospholipid syndrome in pregnancy

Scandinavian Journal of Rheumatology, Supplement

Volumn 27, Issue 107, 1998, Pages 44-47

  Ruiz Irastorza, G ^a,b   Khamashta, M ^a   Hughes, G ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b HOSPITAL DE MENDARO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CORTICOSTEROID; HEPARIN; IMMUNOGLOBULIN; PREDNISONE; ANTICOAGULANT AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ANTIPHOSPHOLIPID SYNDROME; CONFERENCE PAPER; DRUG EFFICACY; FEMALE; HUMAN; INTRAUTERINE GROWTH RETARDATION; OBSTETRIC CARE; PREGNANCY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SPONTANEOUS ABORTION; IMMUNOLOGY; IMMUNOTHERAPY; REVIEW;

ABORTION, SPONTANEOUS; ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; ASPIRIN; FEMALE; HEPARIN; HUMANS; IMMUNOTHERAPY; PREGNANCY;

EID: 0031707424     PISSN: 03013847     EISSN: None     Source Type: Journal    
DOI: 10.1080/03009742.1998.11720760     Document Type: Conference Paper

References (37)

1. Khamashta MA, Mackworth-Young C. Antiphospholipid (Hughes) syndrome: a treatable cause of recurrent pregnancy loss. Br Med J 1997; 314:244.
2. Hughes GRV. Thrombosis, abortion, cerebral disease and lupus anticoagulant. Br Med J 1983; 287:1088-9.
3. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GRV. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332:993-7.
4. Branch DW, Scott JR, Kochenour NK, Hershgold E. Obstetric complications associated with the lupus anticoagulant. N Engl J Med 1985; 313:1322-6.
5. Silveira LH, Hubble CL, Jara LJ, et al. Prevention of anticardiolipin antibody-related pregnancy losses with prednisone and aspirin. Am J Med 1992; 93:403-11.
6. Branch DW, Silver RM, Blackwell JL, Reading JC, Scott JR. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol 1992; 80:614-20.
7. Silveira LH, Espinoza LR. Course of aPL inpatients with primary antiphospholipid syndrome before, during and after pregnancy treated with low dose aspirin (letter). J Rheumatol 1993, 20:1440.
8. Lockshin MD, Drunzin MI, Qamar T. Prednisone does not prevent recurrent fetal death in women with antiphospholipid antibody. Am J Obstet Gynecol 1989; 160:439-43.
9. Cowchock FS, Reece EA, Balaban D, Branch DW, Plouffe L. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin. Am J Obstet Gynecol 1992; 166:1318-23.
10. Silver RK, MacGregor SN, Sholl JS, Hobart JM, Neerhof MG, Ragin A. Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients. Am J Obstet Gynecol 1993; 169:1411-7.
11. Lima F, Khamashta MA, Buchanan NMM, Kerslake S, Hunt BJ, Hughes GRV. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol 1996; 14:131-6.
12. Laskin CA, Bombardier C, Hannah M, et al. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. N Engl J Med 1997; 337:148-53.
13. Silver RM, Branch DW, Scott JR. Prednisone and aspirin in women with recurrent pregnancy loss (letter). N Engl J Med 1997; 337:1629.
14. Granger KA, Farquharson RG. Obstetric outcome in antiphospholipid syndrome. Lupus 1997; 6:509-13.
15. Sánchez-Guerrero J, Alarcón-Segovia D. Course of antiphospholipid antibodies in patients with primary antiphospholipid syndrome before, during and after pregnancy treated with low dose aspirin. Relationship of antibody levels to outcome in 7 patients. J Rheumatol 1992; 19:1083-8.
16. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). Br Med J 1997; 314:253-7.
17. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996; 174:1584-9.
18. Rosove MH, Tabsh K, Wasserstrum N, Howard P, Hahn BH, Kalunian KC. Heparin therapy for pregnant women with lupus anticoagulant or anticardiolipin antibodies. Obstet Gynecol 1990; 75:630-4.
19. Ruffatti A, Orsini A, Di Lenardo L, et al. A prospective study of fifty-three consecutive calcium heparin treated pregnancies in patients with antiphospholipid- related fetal loss. Clin Exp Rheumatol 1997; 499-505.
20. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337:688-98.
21. Inbar O, Blank M, Faden D, Tincani A, Lorber M, Shoenfeld Y. Prevention of fetal loss in experimental antiphospholipid syndrome by low-molecular-weight heparin. Am J Obstet Gynecol 1993; 169:423-6.
22. Hunt BJ, Doughty HA, Majumdar G, et al. Thromboprophylaxis with low molecular weight heparin (fragmin) in high risk pregnancies. Throm Haemost 1997; 77:39-43.
23. Nelson-Piercy C, Letsky E, de Swiet M. Low-molecular-weight heparin for obstetric thromboprophylaxis: Experience of sixty-nine pregnancies in sixty-one women at high risk. Am J Obstet Gynecol 1997; 176:1062-8.
24. Lee LH, Liauw PCY, Ng ASH. Low molecular weight heparin for thromboprophylaxis during pregnancy in 2 patients with mechanical mitral valve replacement. Thromb Haemost 1996; 76:628-30.
25. Dulitzki M, Pauzner R, Langevitz P, Pras M, Many A, Schiff E. Low-molecular-weight heparin during pregnancy and delivery: preliminary experience with 41 pregnancies. Obstet Gynecol 1996; 87:380-3.
26. Ratko TA, Burnett DA, Foulke GE, Matuszewski KA, Sacher RA, and the University Hospital Consortium Expert Pannel for Off-Label Use of Polyvalent Intravenously Administered Immunoglobulin Preparations. Recommendations for off-label use of intravenously administered immunoglobulin preparations. JAMA 1995; 273:1865-70.
27. Spinnato JA, Clark AL, Pierangeli SS, Harris EN. Intravenous immunoglobulin therapy for the antiphospholipid syndrome in pregnancy. Am J Obstet Gynecol 1995; 172:690-4.
28. Kaaja R, Julkunen H, Ämmäla P, Palosuo T, Kurki P. Intravenous immunoglobulin treatment of pregnant patients with recurrent pregnancy losses associated with antiphospholipid antibodies. Acta Obstet Gynecol Scand 1993; 72:63-6.
29. Arnout J, Spitz B, Wittevronge C, Vanrusselt M, Van Assche A, Vermylen J. High-dose intravenous immunoglobulin treatment of a pregnant patient with an antiphospholipid syndrome: immunological changes associated with a successful outcome. Throm Haemost 1994; 71:741-7.
30. Marzusch K, Dietl J, Klein R, Hornung D, Neuer A, Berg PA. Recurrent first trimester spontaneous abortion associated with antiphospholipid antibodies: a pilot study of treatment with intravenous immunoglobulins. Acta Obstet Gynecol Scand 1996; 75:922-6.
31. Gordon C, Raine-Fenning N, Brackley K, Bacon PA, Weaver J, Kilby M. Intravenous immunoglobulin (IVIG) therapy to salvage severely compromised pregnancies in SLE and anti-phospholipid (APL) syndrome (abst). Lupus 1998; 7(suppl. 1):114.
32. Mascola MA, Repke JT. Obstetric management of the high-risk lupus pregnancy. Rheum Dis Clin North Am 1997; 23:119-32.
33. Caruso A, De Carolis S, Ferrazzani S, Valesini G, Caforio L, Mancuso S. Pregnancy outcome in relation to uterine artery flow velocity waveforms and clinical characteristics in women with antiphospholipid syndrome. Obstet Gynecol 1993; 82:970-7.
34. Guzman E, Schulman H, Bracero L, Rochelson B, Farmakides G, Coury A. Uterine-umbilical artery doppler velocimetry in pregnant women with systemic lupus erythematosus. J Ultrasound Med 1992; 11:275-81.
35. Kerslake S, Morton KE, Versi E, et al. Early doppler studies in lupus pregnancy. Am J Reprod Immunol 1992; 28:172-5.
36. Cowchock S, Reece A. Do low-risk pregnant women with antiphospholipid antibodies need to be treated? Am J Obstet Gynecol 1997; 176:1099-10.
37. Hunt BJ, Khamashta MA, Lakasing L, et al. Thromboprophylaxis in antiphospholipid syndrome pregnancies with previous cerebral arterial thrombotic events: is warfarin preferable? (letter). Thromb Haemost 1998; 79:1060-1.